Bank of Canada's July Decision Misunderstood by Some Traders, Senior Official Says
By Paul Vieira
OTTAWA--Some market participants initially misinterpreted the Bank of Canada's message regarding its July decision to cut rates as it pertained to downside economic risks, a senior central bank official said Thursday.
Back in July, the Bank of Canada said that downside risks had taken on increased weight in policy deliberations, given that inflation was nearing a 2% target and there was slack in the economy.
"Some people interpreted this to mean that we believed downside risks had strengthened," said Deputy Governor Nicolas Vincent, in remarks published on the central bank's website Thursday. "What we intended to communicate, however, was that, with the 2% target in sight, we gave increased consideration to the risk that inflation could fall below the target."
Vincent's remarks focused on how the central bank arrives at rate-policy decisions, and didn't touch upon the outlook for rate policy after the Federal Reserve's decision Wednesday to deliver a half-percentage-point rate cut. Nor did Vincent discuss data this week indicating Canadian inflation had reached the Bank of Canada's 2% target, and the implications for rate policy.
Write to Paul Vieira at paul.vieira@wsj.com
(END) Dow Jones Newswires
September 19, 2024 08:48 ET (12:48 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
Undervalued by 25% and Yielding 5%, This Stock Is a Buy
-
Can AI Predict Future Stock Returns?
-
The Best Energy Stocks to Buy Now
-
10 Undervalued Wide-Moat Stocks
-
Obesity Drugs: Can New Firms Take Market Share From Eli Lilly and Novo Nordisk?
-
New 4-Star Stocks
-
Intel Fair Value Left Unchanged Despite Qualcomm Takeover Talk